10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2015 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 11, 2016) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Income Statement [Abstract] | |||
| Revenues: | |||
| Net product sales | $ 2,689,478 | 1,750,762 | 1,425,839 |
| Sanofi collaboration revenue | 758,873 | 541,299 | 430,111 |
| Bayer HealthCare collaboration revenue | 580,488 | 495,555 | 220,289 |
| Other revenue | 74,889 | 31,941 | 28,506 |
| Total revenues | 4,103,728 | 2,819,557 | 2,104,745 |
| Expenses: | |||
| Research and development | 1,620,577 | 1,271,353 | 859,947 |
| Selling, general, and administrative | 838,526 | 519,267 | 346,393 |
| Cost of goods sold | 241,702 | 129,030 | 118,048 |
| Cost of collaboration and contract manufacturing | 151,007 | 75,988 | 37,307 |
| Total expenses | 2,851,812 | 1,995,638 | 1,361,695 |
| Income from operations | 1,251,916 | 823,919 | 743,050 |
| Other income (expense): | |||
| Investment and other income (expense) | 6,283 | 8,157 | (231) |
| Interest expense | (14,241) | (37,372) | (46,437) |
| Loss on Extinguishment of Debt | (18,861) | (33,469) | 0 |
| Total other income (expense) | (26,819) | (62,684) | (46,668) |
| Income before income taxes | 1,225,097 | 761,235 | 696,382 |
| Income tax expense | (589,041) | (423,109) | (282,644) |
| Net income | 636,056 | 338,126 | 413,738 |
| Net income per share - basic | 6.17 | 3.36 | 4.23 |
| Net income per share - diluted | 5.52 | 2.98 | 3.72 |
| Weighted average shares outstanding - basic | 103,061 | 100,612 | 97,917 |
| Weighted average shares outstanding - diluted | 115,230 | 113,413 | 111,290 |
| Statements of Comprehensive Income | |||
| Net income | 636,056 | 338,126 | 413,738 |
| Other comprehensive income: | |||
| Unrealized gain (loss) on marketable securities, net of tax | (43,679) | 53,439 | (22) |
| Comprehensive income | 592,377 | 391,565 | 413,716 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |